Klaus Kutz
Technik-/Wissenschafts-/F&E-Leiter bei PROPANC BIOPHARMA, INC.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
James Nathanielsz | M | 50 | 17 Jahre | |
Julian Kenyon | M | 77 | 17 Jahre | |
Rudolf Fahrig | M | 83 |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | 24 Jahre |
Torsten Fahrig | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
Josef Zelinger | M | 74 | 4 Jahre | |
Johannes Oldenburg | M | - |
University of Bonn
| - |
Bernhard Matter | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
Siegfried Knasmüller | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
Robert Schiestl | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
Clemens Unger | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
Klaus Engel | M | 67 |
University of Bonn
| - |
Frank Perabo | M | 59 |
University of Bonn
| - |
Katrin Vernau | M | - |
University of Bonn
| - |
Lothar Alexander Harings | M | 64 |
University of Bonn
| - |
Robert Lammens | M | - |
University of Bonn
| - |
Andreas Koch | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
Jörg-Christian Heinrich | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
Karsten Buse | M | - |
University of Bonn
| - |
Herbert Müsch | M | - |
RESprotect GmbH
RESprotect GmbH Pharmaceuticals: OtherHealth Technology RESprotect GmbH develops drugs for the treatment of chemotherapeutic disease. It holds interest in the prevention and treatment of chemotherapeutic drug resistance and radiation therapyresistance. The firms offers products for the indication of cancer. The company was founded by Rudolf Fahrig in 2000 and is headquartered in Dresden, Germany. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Deutschland | 16 | 84,21% |
Australien | 3 | 15,79% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Klaus Kutz
- Persönliches Netzwerk